# TAYLOR v. THE SOUTHEASTERN PENNSYLVANIA TRANSPORTATION AUTHORITY (SEPTA)

> District Court, E.D. Pennsylvania · June 27, 2024

URL: https://www.frixlaw.com/law-library/cases/10666742

## Case

- **Court:** District Court, E.D. Pennsylvania
- **Decided:** June 27, 2024
- **Opinion:** 100trialcourt
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10666742

## How later opinions describe it (automated extraction)

- discussing four factors (which are identical to the first four factors identified in Pennypack) that “guide a Rule 37(c)(1) determination” (citing Woodworker’s Supply, Inc. v. Principal Mut. Life Ins. Co., 170 F.3d 985, 993 (10th Cir. 1999))
- finding the expert “unquestionably invades the Court’s province by rendering a legal opinion concerning whether various agents of Refco, SPhinX, and PlusFunds complied with their obligations under federal securities law”
- finding first and second factors weighed against exclusion because the expert’s “new calculations will be based on data from the initial report, which Eaton has been aware of for nearly three years”

## Opinion text

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA
JEREMI TAYLOR, CIVIL ACTION
Plaintiff,
NO. 23-2140-KSM
v.
THE SOUTHEASTERN PENNSYLVANIA
TRANSPORTATION AUTHORITY (SEPTA),
Defendant.
MEMORANDUM
MARSTON, J. June 27, 2024
Plaintiff Jeremi Taylor is a practicing Muslim who works as a construction equipment
operator for Defendant Southeastern Pennsylvania Transportation Authority (“SEPTA”). In this
lawsuit, he contends that SEPTA violated his First Amendment rights and various state and
federal discrimination statutes when it insisted that he drink water during Ramadan so that he
could provide a urine sample for mandatory drug testing. (Doc. No. 5.) To support his claims,
Taylor intends to use the expert testimony of Thomas C. Econome as evidence that under the
applicable federal regulations, SEPTA had discretion to reschedule Taylor’s drug test or, at
minimum, to avoid marking Taylor as having “refused” to take the test when he was unable to
produce a sufficient urine sample. (See Doc. No. 26-1 (Econome’s expert report).) SEPTA has

moved to strike Econome’s expert testimony as providing impermissible legal opinions, or in the
alternative, as inadmissible under the standard outlined in Federal Rule of Evidence 702 and
Daubert v. Merrell Dow Pharmaceuticals, Inc. (See Doc. No. 25.) For the reasons discussed
below, SEPTA’s motion is granted in part and denied in part.
I. BACKGROUND
The facts underlying this case are set out more fully in the contemporaneously filed
Memorandum ruling on the parties’ cross-motions for summary judgment. Because the Court
writes primarily for the parties, we do not repeat those facts at length in this Memorandum, and
instead, include only a brief overview of the drug testing framework, Taylor’s claims, and the

contents of Econome’s expert report and deposition.
A. Regulatory Drug Testing Requirements
As a public transportation service provider and recipient of federal funding, SEPTA must
comply with the safety regulations issued by the DOT’s Federal Transit Administration. See 49
C.F.R. §§ 40.1, 655.3, 655.4. These regulations include drug and alcohol testing requirements
for employees, like Taylor, who perform safety-sensitive functions. Id. §§ 655.4, 655.21. The
relevant regulations are contained in 49 C.F.R. Part 40. See id. § 401(a), (b).
1. Procedures for Random Testing
Under Part 40, SEPTA is required to conduct random drug tests pursuant to a written
testing plan. Id. § 655.21; see also id. §§ 655.12, 655.15 (effective through May 31, 2023).1
SEPTA conducts random tests on a weekly basis that runs from Sunday to Saturday with tests

occurring at various times each day. (Doc. No. 40-2 at ¶ 9; Brown Dep. Tr. at 11:12–15
(testifying that SEPTA conducts tests “24/7”); id. at 23: 3–11). In preparation for those tests,
SEPTA uses an outside vendor to generate a random list of approximately 100 employee names,
which is sent to SEPTA’s Drug and Alcohol Program Manager, Paula Brown, the Thursday
before the testing week begins. (Doc. No. 40-2 at ¶¶ 10–11; Doc. No. 40-14 at ¶ 26; Erinoff
Dep. Tr. at 16:3–8; Brown Dep. Tr. at 12:3–13:9.) Brown “distribute[s] the selections . . . evenly

1 For purposes of this Memorandum, the Court relies on the versions of the regulations that were
in effect in 2022 and 2023 when Taylor claims SEPTA discriminated against it.
throughout the week,” and “at about 3:00 a.m. in the morning” before the selected employee’s
shift, program staff members “start calling people to come in for their testing” either in “the
beginning, middle, or end of their shift.” (Brown Dep. Tr. at 12:3–11); see also 49 C.F.R.
§ 655.45(i) (“A covered employee may be randomly selected for prohibited drug use anytime

while on duty.”). When an employee is notified that they have been selected for testing, “he or
she must proceed immediately to the collection site.” ODAPC, What Employers Need to Know
about DOT Drug and Alcohol Testing, at 19 (June 2015) (explaining that this ensures the
“integrity of the testing process”); see also 49 C.F.R. § 655.45(h) (“Each employer shall require
that each covered employee who is notified of selection for random drug or random alcohol
testing proceed to the test site immediately.”). Anybody that is “not tested within [the one week]
period,” because, for example, they are “sick or on vacation,” and therefore, not working at the
relevant time, is “excused” from testing. (Brown Dep. Tr. at 12:3–11.)
2. Collecting a Urine Sample and the Shy Bladder Procedures
When the employee arrives at the collection site, they are to be given a sealed collection
container, directed to a restroom, and told to “provide a specimen of at least 45 mL, not flush the

toilet, and return to [the service agent] with the specimen.” 49 C.F.R. § 40.63(d) (effective Oct.
1, 2010 to May 31, 2023). The collector then inspects the sample, ensuring it “contains at least
45 mL of urine,” falls within an acceptable temperature range, and does not show any signs of
tampering. Id. § 40.65(a) (effective through May 31, 2023). If the sample is less than 45 mL,
the collector is required to “discard the original specimen” and begin the “‘shy bladder’
procedures” outlined in the regulations. Id.; see also ODAPC, DOT Urine Specimen Collection
Guidelines, at 20 (Jan. 2018) (“If the employee provided an initial insufficient specimen, the
collector discards the insufficient specimen . . . . This is the time when the ‘shy bladder’
collection process starts.”).
Under those procedures, the collector must give the employee another opportunity to
provide a sufficient specimen and should encourage the “employee to drink up to 40 ounces of
fluid, distributed reasonably through a period of up to three hours.” Id. § 40.193(a), (b)(1)(ii)
(effective Jan. 1, 2018 to May 31, 2023). “It is not a refusal to test if the employee declines to

drink.” Id.; accord ODAPC, DOT Urine Specimen Collection Guidelines, at 21 (Jan. 2018). It
is, however, considered a refusal if the employee is unable to provide a sufficient sample during
the three-hour period and there is no medical reason for this failure. Notably, the regulations
state that “[i]f the employee has not provided a sufficient specimen within three hours of the first
unsuccessful attempt to provide the specimen,” the collector “must discontinue the collection,
note the facts” on the collection form, and “immediately notify” the employer’s designated
employee representative (“DER”).2 49 C.F.R. § 40.193(b)(1)(iv) (effective Jan. 1, 2018 to May
31, 2023).
Once notified, the DER “must” consult with the designated medical review officer
(“MRO”)3 and “direct the employee to obtain, within five days, an evaluation from a licensed

physician, acceptable to the MRO, who has expertise in the medical issues raised by the
employee’s failure to provide a . . . sufficient specimen.” Id. § 40.193(c) (effective Jan. 1, 2018
to May 31, 2023). If the physician determines that “[t]here is not an adequate basis for
determining that a medical condition has, or with a high degree of probability could have,
precluded the employee from providing a sufficient amount of specimen,” the MRO reviews the

2 The DER is the “employee authorized by the employer to take immediate action(s) to remove
employees from safety-sensitive duties . . . and to make required decisions in the testing and evaluation
processes.” 49 C.F.R. § 40.3 (effective Jan. 1, 2018 to May 31, 2023). Paula Brown is the DER for
SEPTA. (Brown Dep. Tr. at 23:7–20.)
3 The MRO is the “licensed physician[,] who is responsible for receiving and reviewing
laboratory results generated by an employer’s drug testing program and evaluating medical explanations
for certain drug test results.” 49 C.F.R. § 40.3 (effective Jan. 1, 2018 to May 31, 2023).
physician’s findings and if they agree, the MRO “must” mark the employee as having “refus[ed]
to test.” 49 C.F.R. § 40.193(d)(2) (effective Jan. 1, 2018 to May 31, 2023); see also
id. § 40.191(a)(5) (effective Oct. 1, 2010 to May 31, 2023) (An employee “refuse[s] to take a
drug test” when they “[f]ail to provide a sufficient amount of urine when directed, and it has

been determined, through a required medical evaluation, that there was no adequate medical
explanation for the failure.”). “An MRO’s refusal determination is final and not subject to
[employer] review.” ODAPC, What Employers Need to Know about DOT Drug and Alcohol
Testing, at 28 (June 2015).
3. Consequences of Refusing to Test
When an employee is marked as refusing to submit to a random or follow-up drug test,
they are prohibited from returning to work in a position requiring a safety-sensitive function until
they “meet[ ] the requirements of 49 CFR Part 40 for returning to duty.” 49 C.F.R. § 655.61(b)
(effective through May 31, 2023); accord id. §§ 655.49(a), 655.61(a)(3) (effective through May
31, 2023). The first step in that process is to submit to an evaluation with a substance abuse
professional (“SAP”) and complete any education courses or treatment requirements

recommended by the SAP. Id. §§ 40.285 (effective through May 31, 2023), 40.293 (effective
through May 31, 2023). Once the employee complies with the recommended course of
education or treatment, they are reevaluated by the SAP, who provides a written report to the
DER highlighting the employee’s compliance. Id. § 40.301(c)(1) (effective through May 31,
2023).
If at that point the employer wishes for the employee to “return to the performance of
safety-sensitive functions,” the employee takes a return-to-duty drug test. Id. § 40.305(a)
(effective through May 31, 2023). “The employee must have a negative drug test result . . .
before resuming performance of safety-sensitive duties.” Id. In addition, after returning to duty,
the employee must complete follow-up testing as directed by the SAP. ODAPC, What
Employers Need to Know about DOT Drug and Alcohol Testing, at 18 (June 2015) (“[T]he SAP
can direct more tests and may extend them for up to five years.”).
B. Taylor’s Drug Tests
Taylor has been subject to drug testing under these regulations and SEPTA’s

corresponding policies several times. As relevant here, he was called for random drug testing
during daylight hours on April 6, 2011. (Doc. No. 40-2 at ¶ 55.) When he was unable to
produce a sufficient amount of urine as a sample, the technicians began the shy bladder
procedure and encouraged Taylor to drink water so that he could provide a second sample. (Doc.
No. 40-4 at ¶¶ 32–38.) At first, he refused to drink water because he was fasting for Ramadan,
but when he was told he would be marked as having refused to test if he failed to provide a
second sample, Taylor reluctantly agreed to drink water. (Id. at ¶¶ 44–45.) Despite doing so, he
was unable to provide another sample within the required time frame, and when the MRO found
his failure was not for medical reasons, he was marked as refusing to test. (Id. at ¶¶ 45, 48, 60;
see also Taylor Dep. Tr. at 126:17–131:22.)

This triggered the SAP evaluation process, and when Taylor returned to work, resulted in
Taylor having to take follow-up tests at various times over the next five years. (Doc. No. 40-4 at
¶ 55; Doc. No. 40-23 (referral to SAP, signed by Taylor, who added, “I do not agree to this”);
Doc. No. 40-22 (SAP Follow Up Evaluation).) Two follow-up tests, one in March 2023 and a
second in April 2023, were during Ramadan. (Doc. No. 40-4 at ¶ 77.) Knowing he would be
immediately discharged if he was marked as refusing a second test, Taylor drank water during
each follow-up test to ensure he could produce a sufficient urine sample. (Id. at ¶ 78.)
C. Taylor’s Complaint
Taylor filed this action against SEPTA on June 5, 2023. (See Doc. No. 1.) A few weeks
later, he filed an Amended Complaint, which is the operative pleading. (See Doc. No. 5.) He
brings one claim pursuant to 42 U.S.C. § 1983, contending that SEPTA violated his First
Amendment rights when it “coerced [him] into drinking water in violation of his Ramadan fast in
both 2022 and 2023” and when it refused “to exercise its discretion and enforce DOT regulations

in a nondiscriminatory manner by allowing Mr. Taylor to appear for his drug tests outside of
fasting hours during Ramadan or during one of the eleven (11) other months of the year.” (Doc.
No. 5 at 17.) Taylor also claims that SEPTA’s conduct amounts to religious discrimination in
violation of Title VII of the Civil Rights Act of 1964 and the Pennsylvania Human Relations Act
(“PHRA”). (Id. at 18–20.)
D. Econome’s Expert Report
In support of his claims, Taylor has produced the expert report of Thomas C. Econome.
(See Doc. No. 26-1.) Econome is the President and General Manager of Collection Plus, a
company that serves as a third-party administrator for other businesses’ drug and alcohol testing
needs. (Id. at ¶¶ 7–8.) In that role, Collection Plus has provided drug and alcohol testing and
collection services in California since 2004, seeing more than 900 employees per month, and it

offers consultation services to its clients, providing “advice and counsel as needed for meeting
compliance standards under 49 CFR Part 40.” (Id.) Collection Plus also manages shy bladder
determinations and follow-up testing programs for its clients. (Id. at ¶ 9.) Econome himself is a
certified substance abuse program administrator (C-SAPA), and he is an active member of the
Substance Abuse Program Administration Association (SAPAA). (Id. at ¶ 11.)
In this case, Taylor asked Econome to “render opinions in the areas of [a]dministering a
DOT random testing and follow up program as well as to review the particular procedures to be
utilized when a donor is unable to provide a urine specimen of at least 45 mL.” (Id. at ¶ 16.) In
forming his opinions, Econome considered the depositions taken in this case, along with the
relevant regulations and guidelines. (Id. at ¶ 18.) His report, which is dated December 14, 2023,
includes two overall opinions.
The first opinion relates to the discretion that Part 40 affords employers and DERs during
the random testing process:

Opinion #1—It is [his] opinion that the regulations are not to be
followed “blindly” and a [DER] in any situation, other than certain
MRO reports, has discretion as to when to cancel, delay, or postpone
a drug test and how to handle any rescheduling of a drug and/or
alcohol test. In addition, the DER has authority, even in the middle
of testing, to exercise discretion to stop the process on reasonable
grounds and to administratively close the procedure, essentially
treating the test as a “non-event.”
(Id. at ¶ 24.) In support of this general opinion, he goes on to make five specific “points”:
1. The DOT regulations require the DER to determine whether a
violation of the regulations has taken place but permit the DER to
exercise discretion in making that determination.
2. SEPTA’s DER had the ability to accommodate Mr. Taylor’s
objection to breaking his fast by drinking water during Ramadan.
3. The DER had discretion to cancel or postpone Mr. Taylor’s
scheduled test.
4. Once the process has started, the DER still has discretion to stop
the process.
5. Even after the SAP process was started the DER could have
cancelled that process and reinstated the employee, because more
information was found after the fact.
(Id. at pp. 9–18.)
Econome’s second opinion relates to the discretion that the regulations give employers
during follow-up testing:
Opinion #2—It is [his] opinion that when administering [f]ollow-
[u]p testing there is even more discretion and flexibility in how to
implement Part 40 regulations.
(Id. at ¶ 24.) There are no subparts to this opinion, but Econome concludes that “SEPTA’s DER
had discretion to schedule follow-up testing on dates in March and April of 2023 other than
during Ramadan.” (Id. at p. 19.)
E. Econome’s Deposition
After reviewing Econome’s expert report, SEPTA took his deposition on February 15,
2024, around two weeks shy of the expert discovery deadline. (See Doc. No. 22 at ¶ 2.) During

that deposition, he reiterated the opinions contained in his expert report. He also built on his
prior opinions by providing additional background information about drug testing under the
regulatory framework. Notably, he discussed the typical custom in the industry for selecting
employees for random testing, the protocols in place if an employee fails a drug test, and the
common practice used for scheduling follow-up tests. (Econome Dep. Tr. at 43:21–55:7,
149:21–150:11, 191:19–193:13; see also id. at 74:6–16 (Econome testifying to his “interactions
with MROs” and “other industry trade association professionals” about the requirement that a
collector offer the employee water after they are unable to produce a sufficient sample).)
II. DISCUSSION
SEPTA moves to disqualify Econome from offering his expert opinions, arguing that

they should be excluded because each “opinion is purely a legal conclusion about how he thinks
49 C.F.R. § 40 should be interpreted.” (Doc. No. 26 at 10.) In the alternative, SEPTA argues
that Econome’s opinions are inadmissible under Federal Rule of Evidence 702 and the Supreme
Court’s holding in Daubert. (Id. at 20–22.) Taylor opposes the motion, arguing that Econome is
both qualified and permitted to “render opinions upon the practice and custom of those in the
field conducting drug testing under the Department of Transportation’s regulations.” (Doc. No.
39 at 10.) Taylor also argues that to the extent Econome testified during his deposition about
industry custom and practice, that testimony is admissible. (See Doc. No. 50 at 2.4) SEPTA
disagrees, arguing that any opinions raised for the first time during Econome’s deposition are
inadmissible because they were not included in his expert report as required by Federal Rule of
Civil Procedure 26(a)(2)(B).

The Court first addresses whether the expert opinions in Econome’s expert report are
impermissible legal conclusions, and then considers whether Econome may rely on additional
opinions that were given during his deposition but excluded from the report. Finally, to the
extent any of Econome’s opinions remain, the Court considers those opinions under the
framework outlined in Rule 702 and Daubert.
A. Impermissible Legal Conclusions
A district court has “discretion to determine whether expert testimony will help the trier
of fact” in a given case. Berckeley Inv. Grp., Ltd. v. Colkitt, 455 F.3d 195, 217 (3d Cir. 2006).
In exercising that discretion, however, “the District Court must ensure that an expert does not
testify as to the governing law of the case.” Id. Indeed, although Federal Rule of Evidence 704
permits expert opinions that “embrace[ ] an ultimate issue to be decided by the trier of fact, an

expert witness is prohibited from rendering a legal opinion” because “[s]uch testimony . . . would
usurp the District Court’s pivotal role in explaining the law to the jury.” Id. (quotation marks
omitted); see also FedEx Ground Package Sys., Inc. v. Applications Int’l Corp., 695 F. Supp. 2d
216, 221 (W.D. Pa. 2010) (“It is the duty of the court, not of any witness, to explain the law to
the jury.”).

4 This argument appears in a supplemental brief that Taylor submitted after oral argument. At no
point did the Court request additional briefing on this issue or give Taylor leave to file additional pages in
support of his arguments. As such, the Court would have considered a motion to strike this filing from
the Docket. Nevertheless, because SEPTA has not moved to strike the erroneous filing, and the brief
addresses issues raised at oral argument, the Court will consider the arguments raised within it.
Here, the opinions in Econome’s expert report do just that. In his two general opinions,
Econome purports to interpret the regulations contained in Part 40 and offers a legal conclusion
about the scope of discretion that those regulations afford employers like SEPTA. (See Doc. No.
26-1 at ¶ 24 (framing his first opinion as “a [DER] in any situation . . . has discretion as to when

to cancel, delay, or postpone a drug test and how to handle any rescheduling of a drug and/or
alcohol test. In addition, the DER has authority, even in the middle of testing, to exercise
discretion to stop the process on reasonable grounds and to administratively close the procedure,
essentially treating the test as a “non-event” (emphases added)); id. (framing his second opinion
as “when administering [f]ollow-[u]p testing there is even more discretion and flexibility in how
to implement Part 40 regulations” (emphasis added)).
This conclusion is reinforced by the discussion following each opinion in his report. Of
note, the first point that Econome makes under his first opinion is that “DOT regulations require
the DER to determine whether a violation of the regulations has taken place but permit the DER
to exercise discretion in making that determination.” (Id. at p. 9 (emphases added).) This is

clearly a conclusion about the meaning and scope of the regulations. Indeed, in support of this
point, Econome relies solely on the regulations, quoting multiple portions of Part 40. (Id. at
¶¶ 25–29 (quoting 49 C.F.R. §§ 40.5, 40.7, 40.11, 40.355(g)–(k), (o), 40.193(b)(iii)).)5 And in
his deposition, Econome confirmed that this portion of the report outlines his “interpretation . . .
[of] what th[e] regulation means.” (Econome Dep. Tr. at 133:3–12.) Indeed, during his
deposition Econome confirmed that the “whole point” of his expert testimony was to discuss “the

5 Similarly, in support of the second point raised in connection with his first opinion, Econome
concludes that “[e]mployers must and can implement Part 40 testing requirements while still providing an
accommodation for sincerely held religious beliefs which, by regulation, they are also required to do.”
(Id. at ¶ 36 (emphases added).) This conclusion is supported solely by citations to an unidentified
Administrative Code. (Id. at ¶ 37.) During his deposition, Econome explained that the reference was to
the Administrative Code of New York City and was a mistake on his part. (See Doc. No. 45 at 171:2–11.)
latitude” afforded to “a DER and discretion of a DER to have around anything to do with the
regulations.” (Id. at 67:23–68:3; see also id. at 87:16–88:3 (describing the “question” posed to
him as whether “DER[s] have discretion and latitude in the regulations, and what are some
scenarios both from what I can show in the regulation[s], as well as my experience, where we’ve

applied discretion and have not had an issue with any federal entity around applying that
discretion”).); cf. In re: Tylenol (Acetaminophen) Mktg., Sales Practices, & Products Liab. Litig.,
Civil Action No. 2:12-cv-07263, at *4 n.11 (E.D. Pa. July 27, 2016) (rejecting the plaintiff’s
argument that the expert’s opinion represented a “regulatory fact and not a legal determination”
because “to reach the conclusions which both the court and [the expert] have reached about
acetaminophen’s status under the regulations, one would need to interpret the regulations in
accordance with administrative and general law principles. This is a legal process, not a factual
one”).
In addition to discussing the meaning and scope of the relevant regulations, Econome
also applies his interpretation of the regulations to the facts of this case, opining that SEPTA

could have, and indeed, should have, acted differently toward Taylor. For example, in the third
point of the first opinion, Econome opines that “SEPTA had discretion to postpone or cancel Mr.
Taylor’s April 6, 2022 test.” (Doc. No. 26-1 at ¶ 38.) Similarly, in the fifth point supporting his
first opinion, Econome concludes that “SEPTA’s DER had discretion at multiple stages of the
testing process that was initiated on April 6, 2022 to accommodate Mr. Taylor’ religious belief
by canceling the random test, postponing the test or testing before sunrise or after sunset, or . . .
stopping the entire process and cancelling it administratively.” (Id. at ¶ 48.) Finally, in support
of his second opinion, Econome concludes that “[r]ather than choose to accommodate Mr.
Taylor’s request that he not be tested during Ramadan, which it could easily have done without
violating DOT relations [sic], SEPTA chose not to.” (Id. at ¶ 55.)
Each statement is Econome’s opinion about what was permitted under the regulations and
whether SEPTA’s conduct in Taylor’s case complied with them—opinions which are
impermissible under the case law of this Circuit. See Berckeley Inv. Grp., Ltd., 455 F.3d at 218

(discussing United States v. Leo, 941 F.2d 181 (3d Cir. 1991) and explaining that in Leo, the
expert’s testimony was admissible because “the expert did not give his opinion as to what was
required under the law or whether the defendant complied with the Act” (emphasis added)
(internal citations omitted)); id. (finding that the expert witness in Berckeley could not “testify as
to whether [the plaintiff] complied with legal duties that arose under the federal securities laws,”
i.e., whether the plaintiff’s “sales of NMFS stock were exempt from registration requirements,”
the “legal effect of the various SEC pronouncements” regarding the relevant regulations,” and
whether, “in light of the apparent routine industry practice[,] it was reasonable for [the plaintiff]
to have believed that it was entitled to [a regulatory] exemption”); Krys v. Aaron, 112 F. Supp.
3d 181, 192 (D.N.J. 2015) (finding the expert “unquestionably invades the Court’s province by

rendering a legal opinion concerning whether various agents of Refco, SPhinX, and PlusFunds
complied with their obligations under federal securities law”); FedEx Ground Package Sys., Inc.,
695 F. Supp. 2d at 221–23 (excluding expert opinion where the witness “repeatedly opines as to
what is ‘required under the law,’” about “whether the parties ‘complied with the Act’ or other
statutory requirements,” and whether, “if certain facts are true, then a particular legal conclusion
(i.e., infringement) will follow”); SEC v. McDermott, CIVIL ACTION NO. 19-4229-KSM, 2022
WL 952895, at *13 (E.D. Pa. Mar. 30, 2022) (excluding expert opinion that “MIA and
McDermott failed to act in the best interest of their advisory clients” because such testimony
went “directly to one of the central legal issues in this case—whether Defendants breached their
fiduciary duty to their clients”); In re: Tylenol (Acetaminophen) Mktg., Sales Practices, &
Products Liab. Litig., Civil Action No. 2:12-cv-07263, at *4 (E.D. Pa. July 27, 2016) (excluding
expert opinion “about whether acetaminophen would be considered Generally Recognized as
Safe and Effective, or GRASE” under the relevant FDA regulations, because the opinion “would

require a legal interpretation of the meaning of GRASE,” and although the expert, an attorney
with more than 30 years’ experience, is “qualified to make such an interpretation . . . , it is not
within the scope of his role as an expert. It is for the court to make this legal determination”);
QVC, Inc. v. MJC Am., Ltd., Civil Action No. 08-3830, 2012 WL 13565, at *3 (E.D. Pa. Jan. 4,
2012) (excluding expert’s conclusion that the plaintiff’s letters did “not comport with the
CPSC’s requirements for a product safety recall” because the expert’s opinion “crosses over the
line from admissible testimony to inadmissible legal opinion”); In re Wellbutrin SR Antitrust
Litig., Civil Action Nos. 04–5525, et al., 2010 WL 8425189, at *2 (E.D. Pa. Mar. 31, 2010)
(excluding expert opinions where “large portions of each expert report contain explanation of
specific areas of patent law—including prosecution history estoppel, the doctrine of equivalents,

and the meaning of Warner-Jenkinson—and conclusions of law—including whether GSK had an
objectively reasonable basis to file its 798 patent infringement suits . . . . It is the province of this
court, and not the experts, to educate the jury on those specific areas of law relevant to plaintiffs’
798 patent sham litigation claim”).
Econome’s opinions are particularly problematic in this case because the regulations in
Part 40 changed in May 2023, just after the last drug test challenged by Taylor in this case. As
the Court explains at length in the contemporaneously filed summary judgment Memorandum,
the new regulations and the agency explanation accompanying those regulations provide
significant discussions about the extent of discretion afforded to DERs to cancel a random drug
test and mark it as an administrative non-event. See Addition of Oral Fluid Specimen Testing for
Drugs, 88 F.R. 27596-01, 2023 WL 3173277, at *27623 (May 2, 2023). Econome relies on
those new regulations and the accompanying discussion in support of his opinions, even though
they were promulgated after Taylor’s tests and as such, have little relevance to SEPTA’s actions

in this case. (See Doc. No. 26-1 at ¶¶ 45, 46, 48.)
For those reasons, the Court finds the opinions in Econome’s expert report are
impermissible legal conclusions and precludes Taylor from offering those opinions as evidence
in this case.
B. Opinions Given During a Deposition
Taylor nevertheless argues that “Econome’s testimony does not invade the province of
the Court” because it is “about how employers in the real world exercise their discretion under
the Regulations.” (Doc. No. 39 at 16–17.) He reasons that Econome’s discussion of the
regulations and their scope is merely background information and that this “legal context is
necessary to explaining the custom and practice in the industry” (id. at 17), which he discusses at
length in his deposition (see Doc. No. 50 at 4).

It is true that an expert may permissibly opine about a custom or practice in a particular
industry. See, e.g., In re: Tylenol (Acetaminophen) Mktg., Sales Practices, & Products Liab.
Litig., Civil Action No. 2:12-cv-07263, at *3 (E.D. Pa. July 27, 2016) (“[A]n expert may offer
testimony about business or trade customs and practices without invading the province of the
court.”); McDermott, 2022 WL 952895, at *12 (“Testimony about whether a party’s conduct
comports with industry custom and practice is permissible; testimony about whether a party’s
conduct comports with the law is not.”). Such cases present thorny issues of admissibility,
however, because “the line between admissible and inadmissible expert testimony as to the
customs and practices of a particular industry often becomes blurred when the testimony
concerns a party’s compliance with customs and practices that implicate legal duties.” Berckeley
Inv. Grp., Ltd., 455 F.3d at 218. Courts considering such close cases have noted that “district
courts have discretion to allow expert legal testimony where it would be helpful to the trier of
fact to understand the evidence, but they cannot allow experts to explain the law.” In re

Wellbutrin SR Antitrust Litig., Civil Action Nos. 04–5525, et al., 2010 WL 8425189, at *2 (E.D.
Pa. Mar. 31, 2010) (emphasis added) (quotation marks and citations omitted). “Similarly, expert
testimony is properly admitted to explain the custom in a given field, so long as the expert is not
permitted to opine on what the law required.” Id. (emphasis added) (quotation marks omitted).
The problem with Taylor’s argument is that in his expert report, Econome does not
explain a custom or practice broadly accepted in the industry of regulatory drug testing. Indeed,
the word “custom” does not appear anywhere in Econome’s expert report. Instead, Econome’s
opinions on custom and practices in the drug testing industry appear in his expert deposition,
where, as discussed above, he opined about background drug testing protocols present within the
industry.6

SEPTA argues that the Court cannot consider any additional opinions given during
Econome’s deposition because they were not included in his expert report as required by Federal

6 During his deposition, Econome also testified at length about the advice that he and his
company typically give to clients about, among other things, the “shy bladder procedures [and] protocols”
and about scheduling Muslim employees for testing during Ramadan. (See Econome Dep. Tr. at 28:9–
37:2.) But these “opinions” suffer from the same defect as the opinions contained in Econome’s report.
He is opining about how he interprets the testing regulations and the advice he gives to clients based on
those interpretations; he is not opining about wide-spread industry practices. In addition, although
Econome testified that his Ramadan guidance was “confirmed” by an FTA auditor named George
Gilpatrick, his discussions with Gilpatrick occurred in September or October 2023 (Econome Dep. Tr. at
39:8–40:10, 60:1–62:22), which was after the testing at issue in this case and more importantly, after the
agency issued revised regulations and guidance on the discretion afforded DERs (see id. at 138:19–
139:11 (explaining that his opinions regarding Ramadan were based on the regulations, “as well as
guidance given subsequent,” and his own “personal experience” and “professional experience in running
into various situations to include the Ramadan, and never having an FTA auditor have a finding against
it”)).
Rule of Civil Procedure 26(a)(2)(B). That rule states that an expert witness report must contain
“a complete statement of all opinions the witness will express and the basis and reasons for
them.” Fed. R. Civ. P. 26(a)(2)(B)(i). When a party fails to comply with Rule 26, Federal Rule
of Civil Procedure 37(c)(1) comes into play, and “the party is not allowed to use th[e]

information” excluded from the witness report “unless the failure was substantially justified or is
harmless.” Fed. R. Civ. P. 37(c)(1).
The Third Circuit has held that the exclusion of evidence under Rule 37 is an “‘extreme’
sanction,” the appropriateness of which turns on a number of factors. Meyers v. Pennypack
Woods Home Ownership Assn., 559 F.2d 894 (3d Cir. 1977), overruled on other grounds by
Goodman v. Lukens Steel Co., 777 F.2d 113 (3d Cir. 1985).7 The five “Pennypack factors” are:
(1) ‘the prejudice or surprise in fact of the party against whom
excluded witnesses would have testified’ or the excluded evidence
would have been offered; (2) ‘the ability of that party to cure the
prejudice’; (3) the extent to which allowing such witnesses or
evidence would ‘disrupt the orderly and efficient trial of the case or
of other cases in the court’; (4) any ‘bad faith or willfulness in failing
to comply with the court’s order’; and (5) the importance of the
excluded evidence.
ZF Meritor, LLC v. Eaton Corp., 696 F.3d 254, 298 (3d Cir. 2012) (citing Pennypack, 559 F.2d
at 904–05); see also Gillum v. United States, 309 F. App’x 267, 269 (10th Cir. 2009) (discussing
four factors (which are identical to the first four factors identified in Pennypack) that “guide a
Rule 37(c)(1) determination” (citing Woodworker’s Supply, Inc. v. Principal Mut. Life Ins. Co.,
170 F.3d 985, 993 (10th Cir. 1999))). Here, the Pennypack factors weigh in favor of admitting

7 In this way, the Third Circuit seems to have split from the Seventh Circuit, which held, without
any discussion of Rule 37, that “Rule 26(a)(2) does not allow parties to cure deficient expert reports by
supplementing them with later deposition testimony” because doing so undermines the purpose of the
rule: “to shorten or decrease the need for expert depositions.” Ciomber v. Cooperative Plus, Inc., 527
F.3d 635, 642 (7th Cir. 2008) (citing Salgado v. General Motors Corp., 150 F.3d 735, 741 n.6 (7th Cir.
1998)).
Econome’s testimony about industry customs for selecting employees for random testing, the
protocols in place if an employee fails a drug test, and the common practice used for scheduling
follow-up tests. (Econome Dep. Tr. at 43:21–55:7, 74:6–16, 149:21–150:11, 191:19–193:13.)
As to the first factor, SEPTA will not suffer substantial prejudice or surprise if Taylor is

allowed to rely on Econome’s additional opinions because his opinions as to industry custom are
consistent with the opinions included in his report and largely consistent with SEPTA’s own
procedures for random testing. See ZF Meritor, LLC, 696 F.3d at 298 (finding first and second
factors weighed against exclusion because the expert’s “new calculations will be based on data
from the initial report, which Eaton has been aware of for nearly three years”); cf. Quinn v.
Consol. Freightways Corp. v. Delaware, 283 F.3d 572, 577 (3d Cir. 2002) (“[The defendant]
therefore knew of [the witness’s] testimony for months before attempting to strike it as a last
minute surprise that justified sanctions as a discovery abuse. Not only is it clear that counsel for
[the defendant] was not surprised by evidence of this hotel encounter, but he concedes that any
prejudice from admitting this testimony was minimal at best because it afforded him an

additional avenue to impeach [the plaintiff’s] own testimony.”).
The second factor also weighs against exclusion because SEPTA was not impeded in its
ability to cure what little prejudice it did suffer. SEPTA had an opportunity to question
Econome about his new opinions during the deposition, and to the extent SEPTA believed it
needed to depose Econome again to address, it could have done so during the two weeks
remaining before the close of discovery or asked the Court for additional time. It is telling that
SEPTA did neither. See Bayer HealthCare LLC v. Baxalta Inc., No. 16-cv-1122-RGA, 2019
WL 297039, at *6 (D. Del. Jan. 22, 2019) (“It seems that any prejudice Plaintiff may suffer could
have been cured. Although Plaintiff is not obligated to cure prejudice of Defendants’ making,
the fact that Plaintiff chose not to spend any effort addressing Dr. Zalipsky’s new theories, via a
sur-reply or in deposition, indicates that Plaintiff did not view the new theories as having a
substantial impact on the case. It thus follows that Plaintiff is unlikely to suffer any significant
prejudice from Dr. Zalipsky’s testimony related to those theories. Therefore, the first and second

factors weigh against exclusion.”); Miller v. Trans Union, LLC, Civil No. 3:12–CV–1715, 2015
WL 2089965, at *4 (M.D. Pa. May 6, 2015) (“In short, having been aware of the Stango report
now since January 2015, we are confident that the plaintiff is now fully prepared to meet the
conclusions set forth in that report. Of course, if the plaintiff concludes that he is not fully
prepared to address that report on class certification, he may seek relief in the form of an order
allowing additional time for discovery, or some other lesser remedy, and we are prepared to
consider such a request. However, in this setting, where the plaintiff has eschewed other relief in
favor of exclusion of Dr. Stango's declaration, we do not believe that a balancing of the equities
favors granting this extreme form of relief.”).
As to the third factor, allowing Taylor to rely on Econome’s additional opinions will not

disrupt the orderly and efficient flow of the case. As noted above, the Court contemporaneously
rules on the parties’ cross-motions for summary judgment, and Econome’s permissible opinions
were not material to the Court’s decision on those cross-motions because the Court understands
the regulatory framework from reading the regulations and agency guidance in effect when
Taylor tested in 2022 and 2023. In other words, the Court did not need to consider Econome’s
opinions and there is no need for additional briefing on summary judgment. The only remaining
issue for trial is damages, and, as we discuss in more depth in connection with the fifth
Pennypack factor, Econome’s permissible opinions are likewise of little relevance to that issue.
Cf. ZF Meritor, LLC, 696 F.3d at 298–99 (finding third factor weighed in against exclusion
because “[a]ny concern that granting Plaintiffs’ motion would prevent Eaton from being able to
effectively prepare to address DeRamus’s new damages estimates at trial is no longer relevant,
nor is there any risk that granting Plaintiffs’ motion would excessively delay a trial on liability”).
The fourth factor also weighs in favor of admitting Econome’s additional opinions as to

background and customs because there is no suggestion of bad faith by Taylor. See, e.g., TQ
Delta, LLC v. 2Wire, Inc., Civil Action No. 13-1835-RGA, 2019 WL 1529952, at *2 (D. Del.
Apr. 9, 2019) (finding fourth factor weighed against exclusion because the court found the
timing was not “a result of bad faith or willful deception”); Vectura Limited v. GlaxoSmithKline,
LLC, Civil Action No. 16-638-RGA, 2019 WL 1436296, at *2 (D. Del. April 1, 2019) (same).
Finally, as for the fifth Pennypack factor, the additional opinions provided by Econome is
of minimal importance but not irrelevant. If this case were to proceed to trial on liability,
Econome’s additional opinions could have provided important context for the jury. The
particulars of the drug testing industry are not normally understood by the general public, and
Econome’s discussion of background information and industry customs would provide the jury

with a framework that could have been crucial to it in reaching a decision. That said, this case is
not proceeding to trial on issues of liability for the reasons the Court explains in its
contemporaneously filed Memorandum on the parties’ cross-motions for summary judgment.
Accordingly, the Court finds the fifth Pennypack factor is neutral. See, e.g., Midwest Energy
Emissions Corp. v. Arthur J. Gallagher & Co., Civil Action No. 19-1334-CJB, 2022 WL
17617809, at *1 (D. Del. Dec. 7, 2022) (“Finally, the last Pennypack factor is about neutral.
While Mr. Green's reliance on the license (which he describes in some detail in his expert report)
indicates that the license is somewhat important to Plaintiffs’ damages case, it is just one of
several agreements considered by Mr. Green, and thus Plaintiffs have other probative evidence
on this front.” (cleaned up)); Bayer HealthCare LLC, 2019 WL 297039, at *6 (finding the fifth
factor neutral because “for the same reason that I find insignificant prejudice to Plaintiff, I find
that the new theories lack importance”); Baptiste v. Rohn, Civil Action No. 2013-0104, 2016 WL
1273884, at *6 (D.V.I. Mar. 29, 2016) (“In view of the countervailing considerations, the Court

concludes that this fifth Pennypack factor is neutral—it does not weigh either in favor or against
exclusion of the evidence of lost wages.”); TQ Delta, LLC, 2019 WL 1529952, at *4 (“The fifth
Pennypack factor is neutral. While Dr. Walker's opinions support Defendant's noninfringement
contentions, Defendant, by its own admission, did not realize the need to respond to Dr.
Cooklev’s and Dr. Almeroth's contentions until receipt of Plaintiff's opening summary judgment
brief.”).
In sum, four of the Pennypack factors weigh in favor of allowing Econome’s additional
opinions and one is neutral. Accordingly, the Court declines to strike Econome’s additional
opinions under Rule 37. See Quinn, 283 F.3d at 577 (finding district court abused its discretion
when it struck testimony because “it [wa]s clear that [the defendant] had known about [the

witness’s] description of the hotel incident for over seven months; any prejudice was neutralized
because [the defendant’s] trial counsel was confident he could cross-examine [the plaintiff]
based upon [the witness’s] testimony; there was no suggestion that the trial would be interrupted;
and although the trial court scolded [the plaintiff’s] attorney when she offered reasons for [the
plaintiff] not having supplemented her original deposition testimony, there was no specific
finding of bad faith or willfulness”).
* * *
Because the expert opinions in Econome’s expert report are impermissible legal
conclusions, Econome is foreclosed from offering those opinions in connection with the pending
motions for summary judgment and at trial. Nevertheless, assuming Rule 702 is satisfied,
Econome is permitted to offer custom and practice testimony consistent with the opinions given
during his deposition and as recounted in this Memorandum.
C. Reliability under Rule 702 and Daubert
That leaves SEPTA’s argument that Econome’s permissible opinions are nevertheless

impermissible under Rule 702 and Daubert. Federal Rule of Evidence 702 outlines the
conditions that must be met for a witness to testify as an expert:
A witness who is qualified as an expert by knowledge, skill,
experience, training, or education may testify in the form of an
opinion or otherwise if the proponent demonstrates to the court that
it is more likely than not that:
(a) the expert’s scientific, technical, or other specialized knowledge
will help the trier of fact to understand the evidence or to determine
a fact in issue;
(b) the testimony is based on sufficient facts or data;
(c) the testimony is the product of reliable principles and methods;
and
(d) the expert’s opinion reflects a reliable application of the
principles and methods to the facts of the case.
Fed. R. Evid. 702.8 This Rule requires the trial judge to act as a “gatekeeper,” ensuring that “any
and all expert testimony or evidence is not only relevant, but also reliable.” Pineda v. Ford
Motor Co., 520 F.3d 237, 243 (3d Cir. 2008) (cleaned up); see also Sikkelee v. Precision
Airmotive Corp., No. 4:07-CV-00886, 2021 WL 392101, at *2 (M.D. Pa. Feb. 4, 2021) (“A
district court exercises more control over experts than over lay witnesses,” because “expert
evidence can be both powerful and quite misleading” given “the difficulty in evaluating it.”

8 SEPTA appears to rely on an older version of Rule 702 in its briefing. (Doc. No. 26 at 10.) The
Court uses the current language of Rule 702, which was most recently amended in December 2023.
(quotation marks omitted)). “Daubert’s general holding—setting forth the trial judge’s general
‘gatekeeping’ obligation—applies not only to testimony based on ‘scientific’ knowledge, but
also to testimony based on ‘technical’ and ‘other specialized’ knowledge.” Kumho Tire Co. v.
Carmichael, 526 U.S. 137, 142 (1999).

To be admissible under Rule 702, expert testimony must satisfy “three major
requirements: (1) the proffered witness must be an expert, i.e., must be qualified; (2) the expert
must testify about matters requiring scientific, technical or specialized knowledge; and (3) the
expert’s testimony must assist the trier of fact.” Pineda, 520 F.3d at 244. These factors are often
referred to as “qualification,” “reliability,” and “fit.” See Schneider ex rel. Estate of Schneider v.
Fried, 320 F.3d 396, 404 (3d Cir. 2003) (“We have explained that Rule 702 embodies a trilogy
of restrictions on expert testimony: qualification, reliability, and fit.”).
The party proposing the expert witness must show that each prong—qualification,
reliability, and fit—is satisfied by a preponderance of proof. Oddi v. Ford Motor Co., 234 F.3d
136, 144 (3d Cir. 2000); see also In re Paoli R.R. Yard PCB Litig., 35 F.3d at 743 & 744 n.11

(explaining that the proponent must make more than a prima facie showing that a technique is
reliable); Ellison v. United States, 753 F. Supp. 2d 468, 476 (E.D. Pa. 2010) (“The burden is on
the proponent of the evidence—here the plaintiff—to establish admissibility by a preponderance
of the evidence.”). However, at all times, we must remember that the Rules of Evidence
generally “embody a strong preference for admitting any evidence that may assist the trier of
fact,” and Rule 702 specifically has a “liberal standard of admissibility.” United States v.
Downing, 753 F.2d 1224, 1230 (3d Cir. 1985); see also Oddi, 234 F.3d at 156 (“The test is not
whether the expert might have done a better job.” (cleaned up)).
Here, SEPTA takes issue only with the reliability of Econome’s methods. (See Doc. No.
26 at 20–22.)9 Under the reliability prong, an “expert’s testimony is admissible so long as the
process or technique the expert used in forming the opinion is reliable.” Pineda, 520 F.3d at 247
(quoting In re Paoli R.R. Yard PCB Litig., 35 F.3d at 742); see also Schneider ex rel. Schneider,
320 F.3d at 404 (explaining that Rule 702’s reliability prong looks to whether the proffered

testimony is “based on the methods and procedures of science rather than on subjective belief or
unsupported speculation” (cleaned up)). In other words, the proffered testimony “must be based
on the methods and procedures of science rather than on subjective belief or unsupported
speculation” and the “expert must have good grounds for his or her belief.” Schneider ex rel.
Schneider, 320 F.3d at 404 (cleaned up). Reliability is not intended to be a high standard, “nor is
it to be applied in a manner that requires the plaintiffs to prove their case twice—they do not
have to demonstrate to the judge by a preponderance of the evidence that the assessments of their
experts are correct, they only have to demonstrate by a preponderance of evidence that their
opinions are reliable.” Oddi, 234 F.3d at 145 (quotation marks omitted). “The test of
admissibility is not whether a particular scientific opinion has the best foundation or whether it is

demonstrably correct,” but instead, “whether the particular opinion is based on valid reasoning
and reliable methodology.” Id. at 145–46; see also In re Paoli R.R. Yard PCB Litig., 35 F.3d at
744 (“The grounds for the expert’s opinion merely have to be good, they do not have to be
perfect.”).
SEPTA argues that Econome’s testimony is “inadmissible for its total lack of reliable
methodology,” and because “[e]ven if the court were to find that Mr. Econome did use a reliable
methodology, that methodology has never been applied to drug testing while fasting during

9 Some courts consider whether an expert opinion offers an impermissible legal opinion under the
“fit” prong. For ease of analysis, the Court here views the two issues separately.
Ramadan.” (Doc. No. 26 at 20–22 (referencing eight reliability factors applied in the Third
Circuit).) But this argument, and SEPTA’s strict reliance on the reliability factors first outlined
in Daubert and the Third Circuit’s decision in United States v. Downing, 753 F.2d 1224 (3d Cir.
1985),10 are somewhat misplaced.

Econome’s opinions do not rest upon technical or scientific knowledge, and as such, the
methodology used to formulate those opinions will not consist of a scientific formula or
mathematical equation. As Taylor notes in his briefing (see Doc. No. 39 at 14), the Supreme
Court recognized almost 25 years ago that not all expert testimony is the same:
Engineering testimony rests upon scientific foundations the
reliability of which will be at issue in some cases. In other cases, the
relevant concerns may focus upon personal knowledge or
experience. As the Solicitor General points out, there are many
different kinds of experts, and many different kinds of expertise. . . .
We agree with the Solicitor General that the factors identified in
Daubert may or may not be pertinent in assessing reliability,
depending on the nature of the issue, the expert’s particular
expertise, and the subject of his testimony.
Kumho Tire Co., 256 U.S. at 150 (cleaned up).
This Court has found that Taylor may rely on Econome’s testimony to the extent he
provides relevant background on the DOT’s regulatory framework for drug testing and discusses
customs and practices in the testing industry. His opinions on these issues are based on his 20
years of experience as a testing administrator and a consultant on regulatory compliance, and are,
therefore, reliable. See, e.g., id. (noting that in some cases “the relevant concern may focus upon

10 Those factors are: (1) whether the method consists of a testable hypothesis; (2) whether the
method has been subject to peer review; (3) the known or potential rate of error; (4) the existence and
maintenance of standards controlling the technique’s operation; (5) whether the method is generally
accepted; (6) the relationship of the technique to methods which have been established to be reliable;
(7) the qualifications of the expert witness testifying based on the methodology; and (8) the non-judicial
uses to which the method has been put. Pineda, 520 F.3d at 247–48. As the Court goes on to explain, the
reference to error rates, hypotheses, and peer review shows that the factors are most often applicable to
scientific and technical expertise, as opposed to expertise based on personal knowledge and experience.
personal knowledge or experience”); McDermott, 2022 WL 952895, at *12 (“Ms. Murray’s
testimony rests on her years of experience in the industry, and Courts in this Circuit have
allowed experts to offer testimony based on such experience.” (collecting cases)). Accordingly,
the Court rejects SEPTA’s motion to the extent it challenges the reliability of Econome’s

permissible opinions.
III. CONCLUSION
Because the expert opinions in Econome’s expert report are impermissible legal
conclusions, Taylor is foreclosed from relying on those opinions as admissible evidence. Taylor
may, however, rely on Econome’s opinions to the extent they provide relevant background
information and discuss the customs and practices in the industry prior to May 2023. An
appropriate order follows.

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10666742. Public record. Not legal advice.